Teva Agrees To Hold Off On Generic For Diabetes Drug Byetta
Teva Pharmaceutical Industries Ltd. will be able to market a generic version of AstraZeneca's diabetes drug Byetta by October 2017, according to a patent infringement settlement filed Thursday in Delaware federal...To view the full article, register now.
Already a subscriber? Click here to view full article